Sickle Cell DiseaseEXDRE2NCT06823219
Long-term Endurance Training in Sickle Cell Disease Patients: Impact on Clinical Profile, Physical Fitness, and Quality of Life.
A study testing endurance training program in people with Sickle Cell Disease, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
Sickle cell disease (SCD), the most common genetic disease worldwide and in France, is an inherited haemoglobinopathy characterised by chronic haemolytic anaemia, vaso-occlusive crisis (VOC), acute pain, and multi-organ damage. Read more about this study
- Who is it for?
- Ages 15 years and older
- Conditions the study is for
- Sickle Cell Disease
- What is being tested?
- endurance training program
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteFrance
- Study dates
- 1 Sep 2024to 1 Oct 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Aged over 15 years and 3 months
- Male or female
- Patients with sickle cell disease (HbSS or HbS-βthal0)
- Affiliated to a social security system
- Having freely given their written consent after having been informed of the purpose, the procedure and the potential risks involved
- Patients in stabilised condition at the start of the experiment: at least 1 month after an acute chronic event or at least 3 months after a blood transfusion.
- Patients hospitalised for vaso-occlusive crisis at least once in the last 3 years
Who cannot join
- Patient whose adherence to the protocol is unlikely according to the investigator
- Patients who already partake in regular physical activity (more than 1 hour of moderate-intensity physical activity per week)
- Patients with a chronic inflammatory and/or infectious pathology
- Patients with an intercurrent condition unresolved for less than a month
- Patients hospitalised for cardiac decompensation during the last 12 months
- Patients on anticoagulant treatment or with a pacemaker/defibrillator
Show all 9Show fewer
- Pregnant patients / breastfeeding woman
- Patients deprived of liberty by judicial or administrative decision or patient under guardianship
- Patients unable to understand the objectives and conditions of the study and unable to give cons
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Henri Mondor Hospital
Créteil, 94000
Thomas Dr D'HUMIERES, +331 49 81 26 12, thomas.d'humieres@aphp.fr
About this study
Official title: Evaluation of a Long-term Endurance Training Program in Patients With Sickle Cell Disease: Benefits on Clinical Profile, Physical Fitness and Quality of Life of Patients
Sickle cell disease (SCD), the most common genetic disease worldwide and in France, is an inherited haemoglobinopathy characterised by chronic haemolytic anaemia, vaso-occlusive crisis (VOC), acute pain, and multi-organ damage. Due to anaemia and multiple pulmonary, cardiac, endothelial, muscle, and metabolic dysfunctions, fatigue and poor physical capacity are common in SCD patients and constitute the primary reason for a sedentary lifestyle.
However, recent findings demonstrated in the first randomised, controlled, and prospective study implementing endurance training in SCD that, when adequately calibrated, regular moderate-intensity endurance training is not only safe but also beneficial for patients (primary outcome: improvement of physical ability).
Read more
This pivotal randomised, controlled, prospective study is designed to prove, on a large multicentre cohort, adult and paediatric, including patients with complications and over a longer period (one year).
The objective of the study is to demonstrate the efficacy of participating in a program of regular physical activity to reduce the rate of vaso-occlusive crises requiring hospitalisation and to improve physical ability in patients with SCD.
Read the detailed description
Sickle cell disease (SCD) is an inherited haemoglobinopathy characterised by chronic haemolytic anaemia, vaso-occlusive crisis (VOC), acute pain, and multi-organ damage, making it the most common genetic disease in France. The mutation involves the substitution of glutamic acid by valine at position β6, leading to the synthesis of abnormal haemoglobin (HbS). The properties of HbS differ significantly from those of normal haemoglobin (HbA). Under deoxygenated conditions, HbS tends to polymerize, inducing deformation of the red blood cell (RBC), causing it to take on a sickle shape.
This leads to a very low haemoglobin concentration and haematocrit (typically 6-8 g/dL and 25%-30%, respectively). Anaemia, coupled with arterial desaturation, results in tissue hypoxia. Furthermore, RBCs containing HbS (RBC-HbS) are less deformable and exhibit abnormal adherence properties. The reduced deformability of HbS-containing RBCs, along with the stiffening of sickle-shaped RBCs, impedes their passage through small vessels, potentially causing blockages in capillaries and obstructing microcirculation, leading to the particularly painful vaso-occlusive crisis (VOC).
In patients with SCD, physical exercise has been shown to be physiologically stressful, resulting in severe exercise intolerance.
Exercise limitations in SCD are related to anaemia, as walking for 5 minutes at 5 km/h leads to large elevations in heart rate (~175 beats/min) and blood lactate concentration (6.6 ± 0.4 mmol/L) in patients. This indicates that exercise, which is relatively easy for sedentary healthy adults, is already too difficult for patients with SCD. Additionally, the first lactate threshold is around 30-35 W for women and 44-50 W for men. These extremely low values reflect the significantly reduced physical ability of patients with SCD, suggesting that even common daily tasks are challenging for them.
The National Sports Health Strategy (SNSS) promotes physical activity for chronic conditions, including SCD.
This project aligns with the second axis of the SNSS, which focuses on the development and use of adapted physical activity as a therapeutic treatment for SCD patients.
Endurance training for trained groups involves a submaximal incremental cycling test. The total test duration is expected to range from 9 to 15 minutes. During the last 5 seconds of each step, a blood sample (7 µL) will be taken from the earlobe and immediately analysed (in less than 20 seconds using Lactate Scout+, EKF Diagnostics) to determine the blood lactate concentration ([lactate]b). Exercise should cease when a [lactate]b of 4 mmol/L is reached. This protocol will allow for the determination of exercise powers and heart rates at the first lactate threshold, at 2.5 mmol/L, and at 4 mmol/L. These values will help set the heart rates used during training/physical activity and assess the physical fitness of patients.
The study will occur in four main stages:
- A screening visit ii) An initial evaluation of the patients (W0, Initial Evaluations), which includes two visits: an inclusion visit (V0) and a physical evaluation visit (V1) iii) A 52-week period (W1-W52) where the control group maintains their usual inactive lifestyle, while the trained groups engage in training and/or physical activity following a therapeutic education session (V2apa) iv) The period will be interspersed with evaluations at M6/W25 and followed by evaluations at M12/W52. These evaluations will include two visits (V3 and V4 at M6, and V5 and V6 at M12), similar to V0 and V1.
- Conditions
- Sickle Cell Disease
- Being tested
- endurance training program
- Keywords
- sickle cell disease, , endurance training
- Medical subject headings
- Anemia, Sickle Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
endurance training programOther
Groupe 2: 52 weeks of out-of-hospital physical activity Groupe 3: 8 weeks of in hospital endurance training 3/weeks and 44 weeks of out- of-hospital physical activity
| Study group | Role | What they receive |
|---|---|---|
| trained arm | Experimental | Groupe 2: 52 weeks of out-of-hospital physical activity (The patients of the trained arm with a V̇O2 at SL2 >75% of the predicted V̇O2 at SL2) Groupe 3: 8 weeks of in hospital endurance training 3/weeks and 44 weeks of out- of-hospital physical activity (Patients identified as presenting severity criteria ) Receives: Other: endurance training program |
| untrained arm | No intervention | Groupe 1: 52 weeks of unchanged rhythm |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of vaso-occlusive crises (VOCs) with hospitalisation
determine the hospitalization rate for vaso-occlusive crisis
Measured: 12 months
Exercise capacity and muscle metabolism and characteristics
the change from baseline in the workload at first lactate threshold. A blood sample (7 µL) will be taken from the earlobe and immediately analysed (in less than 20 seconds, Lactate Scout+, EKF Diagnostics) to determine the blood lactate concentration ([lactate]b). Exercise should be stopped when a [lactate]b of 4 mmol/L is reached
Measured: 12 months
Secondary outcomes (10)
Duration of hospitalisation
Measured: 12 months
Median time from the initiation of "treatment" (training or habitual (inactive) lifestyle) to the first and second hospitalised VOC
Measured: 12 months
Number of acute chest syndromes (ACS)
Measured: 12 months
Days of school and job absenteeism
Measured: 12 months
Analgesic intake
Measured: 12 months
6-minute walk test (6MWT) - performed
The 6MWT will assess the endurance and functional capacities of patients. Distance at 6MWT completion will be measured, as well as the time spent under 90% of oxygen saturation during the test. The patients' Rating of Perceived Exertion (RPE) using the 0-10 Borg's scale will be recorded
Measured: 12 months
Echocardiographic Parameters
Left ventricular ejection fraction (LVEF) (%)
Measured: 12 months
Echocardiographic Parameters
Ventricular wall motion (qualitative assessment or mm)
Measured: 12 months
Echocardiographic Parameters
Chamber Dimensions (mm or mL)
Measured: 12 months
Exercise Physiology Parameters
Heart rate (HR) (beats per minute - bpm)
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2025
- Study start1 Sep 2024
- Primary completion1 Oct 2024
- Study completion1 Oct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sickle Cell DiseaseStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, randomised, controlled trial, multicentric, open label
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06823219
- Sponsor's protocol ID
- APHP230822
- Acronym
- EXDRE2
- Status last verified
- Jan 2025
- First submitted
- 6 Feb 2024
- Last updated
- 12 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of a Long-term Endurance Training Program in Patients With Sickle Cell Disease: Benefits on Clinical Profile, Physical Fitness and Quality of Life of Patients
- ClinicalTrials.gov ID
- NCT06823219
- Acronym / sponsor ID
- EXDRE2 / APHP230822
- Conditions
- Sickle Cell Disease
- Keywords
- sickle cell disease, , endurance training
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 1 Sep 2024 (actual)
- Primary completion
- 1 Oct 2024 (actual)
- Study completion
- 1 Oct 2028 (estimated)
- First posted
- 12 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sickle cell disease (SCD), the most common genetic disease worldwide and in France, is an inherited haemoglobinopathy characterised by chronic haemolytic anaemia, vaso-occlusive crisis (VOC), acute pain, and multi-organ damage. Due to anaemia and multiple pulmonary, cardiac, endothelial, muscle, and metabolic dysfunctions, fatigue and poor physical capacity are common in SCD patients and constitute the primary reason for a sedentary lifestyle.
However, recent findings demonstrated in the first randomised, controlled, and prospective study implementing endurance training in SCD that, when adequately calibrated, regular moderate-intensity endurance training is not only safe but also beneficial for patients (primary outcome: improvement of physical ability).
This pivotal randomised, controlled, prospective study is designed to prove, on a large multicentre cohort, adult and paediatric, including patients with complications and over a longer period (one year).
The objective of the study is to demonstrate the efficacy of participating in a program of regular physical activity to reduce the rate of vaso-occlusive crises requiring hospitalisation and to improve physical ability in patients with SCD.
Detailed description
Sickle cell disease (SCD) is an inherited haemoglobinopathy characterised by chronic haemolytic anaemia, vaso-occlusive crisis (VOC), acute pain, and multi-organ damage, making it the most common genetic disease in France. The mutation involves the substitution of glutamic acid by valine at position β6, leading to the synthesis of abnormal haemoglobin (HbS). The properties of HbS differ significantly from those of normal haemoglobin (HbA). Under deoxygenated conditions, HbS tends to polymerize, inducing deformation of the red blood cell (RBC), causing it to take on a sickle shape.
This leads to a very low haemoglobin concentration and haematocrit (typically 6-8 g/dL and 25%-30%, respectively). Anaemia, coupled with arterial desaturation, results in tissue hypoxia. Furthermore, RBCs containing HbS (RBC-HbS) are less deformable and exhibit abnormal adherence properties. The reduced deformability of HbS-containing RBCs, along with the stiffening of sickle-shaped RBCs, impedes their passage through small vessels, potentially causing blockages in capillaries and obstructing microcirculation, leading to the particularly painful vaso-occlusive crisis (VOC).
In patients with SCD, physical exercise has been shown to be physiologically stressful, resulting in severe exercise intolerance.
Exercise limitations in SCD are related to anaemia, as walking for 5 minutes at 5 km/h leads to large elevations in heart rate (~175 beats/min) and blood lactate concentration (6.6 ± 0.4 mmol/L) in patients. This indicates that exercise, which is relatively easy for sedentary healthy adults, is already too difficult for patients with SCD. Additionally, the first lactate threshold is around 30-35 W for women and 44-50 W for men. These extremely low values reflect the significantly reduced physical ability of patients with SCD, suggesting that even common daily tasks are challenging for them.
The National Sports Health Strategy (SNSS) promotes physical activity for chronic conditions, including SCD.
This project aligns with the second axis of the SNSS, which focuses on the development and use of adapted physical activity as a therapeutic treatment for SCD patients.
Endurance training for trained groups involves a submaximal incremental cycling test. The total test duration is expected to range from 9 to 15 minutes. During the last 5 seconds of each step, a blood sample (7 µL) will be taken from the earlobe and immediately analysed (in less than 20 seconds using Lactate Scout+, EKF Diagnostics) to determine the blood lactate concentration ([lactate]b). Exercise should cease when a [lactate]b of 4 mmol/L is reached. This protocol will allow for the determination of exercise powers and heart rates at the first lactate threshold, at 2.5 mmol/L, and at 4 mmol/L. These values will help set the heart rates used during training/physical activity and assess the physical fitness of patients.
The study will occur in four main stages:
- A screening visit ii) An initial evaluation of the patients (W0, Initial Evaluations), which includes two visits: an inclusion visit (V0) and a physical evaluation visit (V1) iii) A 52-week period (W1-W52) where the control group maintains their usual inactive lifestyle, while the trained groups engage in training and/or physical activity following a therapeutic education session (V2apa) iv) The period will be interspersed with evaluations at M6/W25 and followed by evaluations at M12/W52. These evaluations will include two visits (V3 and V4 at M6, and V5 and V6 at M12), similar to V0 and V1.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Prospective, randomised, controlled trial, multicentric, open label
| Arm | Type | Receives |
|---|---|---|
| trained arm | Experimental | Other: endurance training programGroupe 2: 52 weeks of out-of-hospital physical activity (The patients of the trained arm with a V̇O2 at SL2 >75% of the predicted V̇O2 at SL2) Groupe 3: 8 weeks of in hospital endurance training 3/weeks and 44 weeks of out- of-hospital physical activity (Patients identified as presenting severity criteria ) |
| untrained arm | No intervention | –Groupe 1: 52 weeks of unchanged rhythm |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (7 listed)
- Aged over 15 years and 3 months
- Male or female
- Patients with sickle cell disease (HbSS or HbS-βthal0)
- Affiliated to a social security system
- Having freely given their written consent after having been informed of the purpose, the procedure and the potential risks involved
Key exclusion criteria (9 listed)
- Patient whose adherence to the protocol is unlikely according to the investigator
- Patients who already partake in regular physical activity (more than 1 hour of moderate-intensity physical activity per week)
- Patients with a chronic inflammatory and/or infectious pathology
- Patients with an intercurrent condition unresolved for less than a month
- Patients hospitalised for cardiac decompensation during the last 12 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| endurance training programGroupe 2: 52 weeks of out-of-hospital physical activity Groupe 3: 8 weeks of in hospital endurance training 3/weeks and 44 weeks of out- of-hospital physical activity | Other | trained arm |
Primary outcome
Number of vaso-occlusive crises (VOCs) with hospitalisation
Time frame: 12 months
determine the hospitalization rate for vaso-occlusive crisis
Exercise capacity and muscle metabolism and characteristics
Time frame: 12 months
the change from baseline in the workload at first lactate threshold. A blood sample (7 µL) will be taken from the earlobe and immediately analysed (in less than 20 seconds, Lactate Scout+, EKF Diagnostics) to determine the blood lactate concentration ([lactate]b). Exercise should be stopped when a [lactate]b of 4 mmol/L is reached
10 secondary outcomes
Duration of hospitalisation
Time frame: 12 months
Median time from the initiation of "treatment" (training or habitual (inactive) lifestyle) to the first and second hospitalised VOC
Time frame: 12 months
Number of acute chest syndromes (ACS)
Time frame: 12 months
Days of school and job absenteeism
Time frame: 12 months
Analgesic intake
Time frame: 12 months
6-minute walk test (6MWT) - performed
Time frame: 12 months
Echocardiographic Parameters
Time frame: 12 months
Echocardiographic Parameters
Time frame: 12 months
Echocardiographic Parameters
Time frame: 12 months
Exercise Physiology Parameters
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Sickle Cell Disease
Active, not recruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Sickle Cell Disease, Hemolytic Anemia
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
RecruitingPhase 1
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Sickle Cell Disorders, Sickle Cell Disease
RecruitingPhase 4
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Not yet recruitingPhase 1
Buprenorphine for the Management of Pain in Children With Sickle Cell Disease
Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing endurance training program in people with Sickle Cell Disease, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of vaso-occlusive crises (VOCs) with hospitalisation (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2025.